Patents Examined by Jay Williams
-
Patent number: 6146643Abstract: The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.Type: GrantFiled: June 7, 1995Date of Patent: November 14, 2000Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Sergei A. Tsarev, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 6051373Abstract: Disclosed is a method for screening for inhibitors of Hepatitis B Virus pX activity. The method involves contacting a test compound with (I) the pX protein of HBV, (ii) a transcription factor comprising the bZIP domain, or fragments that comprise a minimal a bZIP domain, and (iii) an oligoduplex comprising a target DNA sequence of the transcription factor to form a test mixture. After incubating the test mixture under appropriate conditions and for a sufficient time to allow pX-mediated dimerization and DNA binding of the transcription factor to occur, the level of DNA binding of the transcription factor in each test mixture is determined. A test compound is considered to be any compound that causes a decrease in the level of DNA binding in the test mixture relative to the level of DNA binding in control mixtures.Type: GrantFiled: December 7, 1994Date of Patent: April 18, 2000Assignees: Scriptgen Pharmaceuticals, Inc., University of Massachusetts Medical CenterInventors: Michael R. Green, Giovanni Perini, James Lillie
-
Patent number: 6037455Abstract: The present invention is directed to novel propoxyphene derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to propoxyphene and propoxyphene metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: November 9, 1992Date of Patent: March 14, 2000Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth F. Buechler
-
Patent number: 6030612Abstract: The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homology with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme.Type: GrantFiled: June 7, 1995Date of Patent: February 29, 2000Assignee: Phairson Medical Inc.Inventors: Johan R. de Faire, Richard L. Franklin, John Kay, Ragnvald Lindblom
-
Patent number: 6008327Abstract: The present invention relates to peptides immunochemically reactive with antibodies to the Epstein-Barr virus (EBV), comprising at least part of the VCA-p18 or VCA-p40 protein, encoded within the EBV open reading frames BFRF3 and BdRF1 respectively, or a functional variant thereof. The invention further relates to nucleic acid sequences encoding these peptides, monoclonal antibodies against these peptides, cell lines capable of producing monoclonal antibodies and anti-idiotype antibodies. The invention also relates to recombinant vector molecules comprising a nucleic acid sequence according to the invention and host cells transformed or transfected with these vector molecules. The invention is further concerned with immunological reagents and methods for the detection of EBV or anti-EBV antibodies and a method for the amplification and detection of Epstein Barr viral nucleic acid.Type: GrantFiled: April 3, 1995Date of Patent: December 28, 1999Assignee: Akzo Nobel, N.V.Inventors: Jaap M. Middeldorp, Wouterus M. J. van Grunsven
-
Patent number: 5981199Abstract: This invention provides a method for measuring an antigen concentration in a sample, which comprises: preparing VH-domain polypeptide and VL-domain polypeptide of an antibody specific to the antigen; labeling one of the polypeptides with a reporter molecule to form labeled polypeptides, and immobilizing the other polypeptides onto solid-phase to form immobilized polypeptides; contacting the antigen-containing sample and the labeled polypeptides with the solid-phase; and measuring the reporter molecule of the labeled polypeptides bound to the immobilized polypeptides. The present invention permits simpler and quicker sandwich ELISA for measurements of an antigen concentration in high sensitivity.Type: GrantFiled: June 14, 1996Date of Patent: November 9, 1999Assignee: Boehringer Mannheim CorporationInventors: Hiroshi Ueda, Teruyuki Nagamune, Hajime Nishimura, Izumi Kumagai, Kouhei Tsumoto, Walter C. Mahoney, Greg Winter, Paula A. Schueler
-
Patent number: 5962317Abstract: A monitoring system such as a drug dosage modeling system is disclosed. In preferred embodiments, the system provides mixing without the need for mechanical stirring.Type: GrantFiled: October 11, 1996Date of Patent: October 5, 1999Assignee: The Johns Hopkins University School of MedicineInventors: Fayez M. Hamzeh, Paul S. Lietman
-
Patent number: 5958676Abstract: A diagnostic assay for detecting the presence of an infectious herpesvirus in a specimen and a genetically engineered cell line for use in such assay are disclosed. The cell line used in the assay expresses a reporter gene only if infectious herpesvirus is present in the specimen. The assay involves inoculating a DNA-transfected cell line with a specimen suspected of containing a herpesvirus, allowing a sufficient period of time for the herpesvirus infectious cycle to proceed, and detecting and quantifying the number of herpesvirus-infected cells to determine the number of infectious herpesvirus virions in the specimen. The cell line is a DNA-transfected cell line susceptible to infection by a herpesvirus which is stably transformed with a chimeric gene comprising a herpesvirus inducible promoter and a gene coding for an enzyme, the expression of the enzyme being dependent upon and quantitatively proportional to the presence of herpesvirus. A kit for such assay is also provided.Type: GrantFiled: April 25, 1997Date of Patent: September 28, 1999Assignee: Washington UniversityInventor: Paul D. Olivo
-
Patent number: 5958406Abstract: The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homology with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme.Type: GrantFiled: February 8, 1996Date of Patent: September 28, 1999Assignee: Phairson Medical Inc.Inventors: Johan R. de Faire, Richard L. Franklin, John Kay, Ragnvald Lindblom
-
Patent number: 5945102Abstract: The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homology with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme.Type: GrantFiled: February 8, 1995Date of Patent: August 31, 1999Assignee: Phairson Medical Inc.Inventors: Johan R. de Faire, Richard L. Franklin, John Kay, Ragnvald Lindblom
-
Patent number: 5935778Abstract: The invention concerns a method for typing antibodies in a sample liquid by means of type-specific antigens and in particular a method for typing antibodies to the hepatitis C virus and peptide antigens suitable for this.Type: GrantFiled: April 28, 1997Date of Patent: August 10, 1999Assignee: Boehringer Mannheim GmbHInventors: Cristoph Seidel, Ursula-Henrike Wienhues-Thelen, Urban Schmitt, Gunther-Gerhard Jung, Hans-Georg Ihlenfeldt, Wolfgang Kraas
-
Patent number: 5932219Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta., of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.Type: GrantFiled: May 25, 1995Date of Patent: August 3, 1999Assignee: Chiron CorporationInventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy Joan Weiner, Lacy Rasco Overby
-
Patent number: 5932468Abstract: An efficient industrial method, by incubation at extreme (alkaline) pH in a stabilized medium, of inactivating viruses in general (with or without a lipid envelope) in media containing proteins for therapeutic use, without denaturing or significant loss of biological activity.Type: GrantFiled: November 1, 1996Date of Patent: August 3, 1999Assignee: Grupo Grifols, S.A.Inventor: Pere Ristol Debart
-
Patent number: 5925512Abstract: Mutant Hepatitis B Virus (HBV) nucleic acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HBV nucleic acid sequences, HBV immunogenic particles, and a method for producing antibodies to HBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HBV nucleic acid sequences.Type: GrantFiled: May 23, 1995Date of Patent: July 20, 1999Assignee: Abbott LaboratoriesInventors: William F. Carman, Richard H. Decker, Lesley Wallace, Larry T. Mimms, Larry R. Solomon
-
Patent number: 5879685Abstract: Immunostimulating reconstituted influenza virosomes (IRIVs) are provided wherein an antigen or a combination of antigens are incorporated into a virosome further containing a mixture of phospholipids, an essentially reconstituted functional virus envelope, and influenza hemagglutinin protein (HA). The HA induces fusion of the IRIV with cellular membranes and thereby induces lysis of the IRIV after its endocytosis by antigen presenting cells.Type: GrantFiled: April 11, 1994Date of Patent: March 9, 1999Assignee: Schweiz, Serum- & Impfinstitut BernInventors: Reinhard Gluck, Robert Mischler
-
Patent number: 5858802Abstract: The invention relates to a device including a substrate and at least one biologically active substance bound to at least a part of the surface of this substrate, which is obtained by simultaneous or sequential reaction of said substrate and of said substance with a bifunctional coupling agent in which one of the functional groups is capable of being photoactivated and generates carbenes and is used to bind the coupling agent to the inorganic substrate and the other functional group is used to bind the coupling agent to the biologically active substance, in which said substrate is a covalent inorganic nitride.Type: GrantFiled: July 19, 1996Date of Patent: January 12, 1999Assignee: CSEM - Centre Suisse d'Electronique et de Microtechnique SAInventors: Hui Chai-Gao, Reto Luginbuhl, Hans Sigrist, Nigel Skinner, Hendrik Van Den Vlekkert
-
Patent number: 5837260Abstract: A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.Type: GrantFiled: June 7, 1995Date of Patent: November 17, 1998Assignee: The United of America as represented by the Department of Health and Human ServicesInventors: Jeffrey I. Cohen, Robert H. Purcell, Stephen M. Feinstone, John R. Ticehurst
-
Patent number: 5773285Abstract: A method for culturing an organic tissue comprising: attaching the tissue onto an inner side of a mesh which is placed in an incubation chamber, and culturing the tissue in the presence of a culture medium and a gas containing oxygen under a condition that the ratio of the contact time of the tissue with the culture medium to that with the gas lies in a range from 1:2.5 to 1:3.5.Type: GrantFiled: November 9, 1995Date of Patent: June 30, 1998Inventor: Sung-Su Park
-
Patent number: 5747044Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta., of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.Type: GrantFiled: May 24, 1995Date of Patent: May 5, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy Joan Weiner, Lacy Rasco Overby
-
Patent number: 5716623Abstract: Isolated viral proteins, and compositions made therefrom, are disclosed which are capable of binding to Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The isolated viral proteins also act as superantigens.Type: GrantFiled: June 6, 1995Date of Patent: February 10, 1998Assignee: Immunex CorporationInventors: Zhengbin Yao, Melanie K. Spriggs, Mark Alderson, Richard J. Armitage